Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Los Angeles, California 90095


RATIONALE: Drugs used in chemotherapy, such as ABI-007, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well ABI-007 works in treating patients with inoperable (unresectable) locally recurrent or metastatic melanoma.

Study summary:

OBJECTIVES: Primary - Determine the antitumor activity of ABI-007 in patients with inoperable locally recurrent or metastatic melanoma. - Determine the safety and tolerability of this drug in these patients. Secondary - Determine the time to disease progression, in terms of the rate and duration of response or stable disease, in patients treated with this drug. - Determine the survival of patients treated with this drug. - Determine the effects of this drug on biomarkers of melanoma in these patients. - Correlate biomarker levels with response in patients treated with this drug. OUTLINE: This is an open-label, multicenter study. Patients are assigned to 1 of 2 treatment cohorts according to prior cytotoxic chemotherapy (previously treated vs chemotherapy-naïve). - Cohort I (previously treated): Patients receive ABI-007 IV over 30 minutes on days 1, 8, and 15. - Cohort II (chemotherapy-naïve): Patients receive a higher dose of ABI-007 as in cohort I. In both cohorts, courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients are followed monthly for 6 months and then every 3 months thereafter. PROJECTED ACCRUAL: A total of 24-70 patients (12-35 per cohort) will be accrued for this study.


DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed melanoma - Inoperable locally recurrent or metastatic disease - Measurable disease - No lytic or blastic bone metastasis as only evidence of metastasis - Prior radiotherapy to a target lesion allowed provided there has been clear progression of disease since completion of radiotherapy - No active brain metastasis, including leptomeningeal involvement - Prior brain metastasis allowed provided the disease is in complete remission for at least 1 month after therapy PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-1 Life expectancy - More than 12 weeks Hematopoietic - Absolute neutrophil count ≥ 1,500/mm^3 - Platelet count ≥ 100,000/mm^3 - Hemoglobin ≥ 9 g/dL Hepatic - AST and ALT ≤ 2.5 times upper limit of normal (ULN) - Alkaline phosphatase ≤ 2.5 times ULN (unless bone metastasis is present in the absence of liver metastasis) - Bilirubin ≤ 1.5 mg/dL Renal - Creatinine ≤ 1.5 mg/dL Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective barrier contraception 1 month before and during study participation - No pre-existing peripheral neuropathy ≥ grade 2 - No prior allergy or hypersensitivity to study drug - No concurrent clinically significant illness - No other concurrent active malignancy - No serious medical risk factors involving any of the major organ systems that would preclude study participation PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - Recovered from prior chemotherapy - More than 4 weeks since prior cytotoxic chemotherapy - At least 3 weeks since prior anthracyclines - No concurrent taxane or anthracyclines - No concurrent doxorubicin Endocrine therapy - No concurrent steroids except as needed for hypersensitivity to study drug Radiotherapy - See Disease Characteristics - Concurrent radiotherapy to a symptomatic non-target lesion (including recurrent or new brain metastases that develop during study participation) allowed Surgery - Not specified Other - More than 4 weeks since prior investigational drugs and recovered - No other concurrent anticancer therapy - No concurrent participation in another clinical study - No other concurrent investigational therapies - No concurrent ritonavir, saquinavir, indinavir, or nelfinavir



Primary Contact:

Study Chair
Antoni Ribas, MD
Jonsson Comprehensive Cancer Center

Backup Contact:


Location Contact:

Los Angeles, California 90095
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.